Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 23, 2022
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
Journal: Journal for immunotherapy of cancer
Published: January 26, 2021
Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families.
Journal: Blood
Published: April 20, 2020
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
Journal: The Lancet. Oncology
Published: February 28, 2020
CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: February 13, 2020
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200.
Journal: Journal for immunotherapy of cancer
Published: May 20, 2019
Characteristics and treatment patterns among US patients with hairy cell leukemia: a retrospective claims analysis.
Journal: Journal of comparative effectiveness research
Published: May 10, 2017
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.
Journal: Nature communications
Published: December 28, 2016
Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial.
Journal: The Lancet. Haematology
Published: February 03, 2016
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.
Journal: Leukemia research
Published: September 03, 2014
Last Updated: 09/26/2026